Taiwan’s pacemakers’ market is set for stable expansion, driven by the rising demand and a gradual move by clinicians and patients to favor durability, innovation, and demonstrable clinical benefits. Reflecting this transition, the country’s pacemakers market is expected to experience a 3% compound annual growth rate (CAGR) between 2026 and 2036, according to GlobalData, a leading data, and analytics company.
GlobalData’s report, “Pacemakers Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036,”reveals that dual‑chamber leadless pacemakers are among the fastest‑growing segments within cardiac rhythm management than traditional pacemakers with leads.
The first implantations of Abbott’s AVEIR DR dual-chamber leadless pacemaker at National Taiwan University Hospital (NTUH) in Taiwan represented a significant milestone. NTUH was Taiwan’s sole participating site in the global AVEIR Dual-Chamber Leadless i2i IDE Study, which began in 2023 and involved the implantation of the device in five patients.
Nearly three years of follow-up data from the trial demonstrated reliable device performance and strong atrioventricular synchronization. Taiwan’s Food and Drug Administration granted market approval for the system in September 2025, a development expected to enhance Abbott’s competitive position in the local market, which GlobalData notes is currently dominated by Medtronic, Boston Scientific, and Biotronik.
Aakansha Pankaj, Medical Devices Analyst at GlobalData, comments, “The introduction of dual-chamber leadless technology fundamentally reshapes the competitive landscape by addressing an unmet clinical need affecting the pacemaker users who need pacing in two chambers of the heart to treat slow or abnormal heart rhythms.”
The Asia-Pacific (APAC) region represents a growth opportunity for leadless pacing technology, with clinical adoption accelerating across major healthcare systems. The three major conditions indicated for fitment of pacemakers are atrial fibrillation, atrioventricular block and sick sinus syndrome.
GlobalData estimates nearly 25.8 million people in the APAC region to be living with or diagnosed with these conditions in 2035. Yet adoption rates are much lower than advanced economies, such as Germany, Japan and the US, where adoption might be 3-5% of the patient population, compared to less than 1% in countries such as China and India, and typically 1.5-2% in Taiwan. This underscores the potential for increased demand through the transformation of healthcare delivery and availability.
Over the next decade, devices combining durable design, reliable performance, and smooth integration with digital monitoring platforms are likely to set the standard. Abbott’s AVEIR DR system, the world’s first dual-chamber leadless pacemaker, has significantly shifted the pacemaker market dynamics, particularly by outperforming Medtronic’s Micra AV2 (which only delivers ventricular therapy and covers around 50% of the pacemaker market needs). The AVEIR DR can address up to 95% of clinical indications, meaning Abbott has successfully captured notable market share from its rivals.
Pankaj concludes: “As Taiwan integrates dual-chamber leadless systems into routine clinical practice, adoption will likely accelerate across high-volume cardiac centers serving the region’s substantial annual pacemaker candidate population. While premium pricing and specialized implantation training requirements may initially moderate uptake, the demonstrated reduction in procedural complications and improved patient quality of life position dual-chamber leadless pacing as the emerging standard of care for comprehensive bradycardia management.”
